Skip to main content
CELC
NASDAQ Industrial Applications And Services

Celcuity Q2 Loss Widens to $78.9M as Launch Spending Ramps; Cash Runway to 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$88
Mkt Cap
$4.223B
52W Low
$44.42
52W High
$151.02
52W Position info
98% above low
Off High info
42% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

CELC sits 98% above its 52-week low of $44.42.

Summary

Celcuity reported a wider Q2 net loss of $78.9M on higher launch spending, with $754M in cash providing runway into 2029. The company highlighted NCCN Category 1 status for REVTORPYK and positive PIK3CA mutant data ahead of a Q3 sNDA submission.


Key Events · Earnings and Guidance · CELC

  • Q2 Net Loss Widens on Launch Spending

    Net loss was $78.9M ($1.44/share) vs $45.3M ($1.04/share) a year ago, driven by a $27.4M increase in SG&A to $35.0M, of which $23.4M related to commercial headcount and launch activities.

  • Cash Runway Extended to 2029

    Cash, cash equivalents and short-term investments totaled $754.0M at June 30, 2026, which management expects will fund operations at least into 2029.

  • NCCN Category 1 Recommendation

    REVTORPYK in combination with fulvestrant, with or without palbociclib, received a preferred Category 1 recommendation for second-line HR+/HER2- advanced breast cancer.

  • PIK3CA Mutant Cohort Positive; sNDA Planned

    VIKTORIA-1 PIK3CA mutant cohort met its primary endpoint (HR=0.50, p<0.0001); Celcuity plans to submit an sNDA to the FDA in Q3 2026.


Analysis · CELC · Industrial Applications And Services

Celcuity's second-quarter loss widened to $78.9 million from $45.3 million a year earlier, driven by a $27.4 million surge in SG&A as the company built out its commercial infrastructure for REVTORPYK. The company holds $754 million in cash and investments, enough to fund operations into 2029, and reiterated a late-Q3 commercial launch timeline. The NCCN Category 1 recommendation and positive PIK3CA mutant cohort data strengthen the launch narrative, but the near-term focus is on execution and the planned sNDA submission in Q3.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CELC was trading at $88.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $44.42 to $151.02. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CELC - Latest Insights

CELC
Nov 09, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $66.32
Real-time Price: $56.03 info
Change: -$10.29 (-16%) info
Market Cap: $2.761B info
CELC
Nov 05, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $56.03 info
Change: -$8.02 (-13%) info
Market Cap: $2.761B info
CELC
Nov 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $56.03 info
Change: -$8.02 (-13%) info
Market Cap: $2.761B info
CELC
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $56.03 info
Change: -$8.02 (-13%) info
Market Cap: $2.761B info
CELC
Sep 30, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $79.00
Real-time Price: $56.03 info
Change: -$22.98 (-29%) info
Market Cap: $2.761B info